Literature DB >> 8997588

A retrospective study of ocular side effects in children undergoing bone marrow transplantation.

R De Marco1, D A Dassio, P Vittone.   

Abstract

Bone marrow transplantation (BMT) is recognized as a successful treatment for malignant and non-malignant hematological diseases. Thanks to transplantation, the number of long-term survivors has risen and with the improved prognosis a problem of ocular side effects has arisen. We carried out a retrospective study to determine the incidence and etiopathogenesis of ocular complications in a series of young patients undergoing BMT. One hundred children (62 males and 38 females) with a mean age of 7.12 (+/- 3.3) years at the time of BMT (autologous in 66 cases, allogenic in 34) were followed for a mean of 4.2 years (range 2-9). The conditioning regimens preceding BMT induced cytoreductive chemotherapy alone (47 cases) or associated with total body irradiation (TBI) (53 cases) in three or six fractions for a total dose of 10-12 Gy. We examined every child before BMT and subsequently every six months. We did not include patients with ocular complications due to the primary disease. Thirty-three children showed several complications after BMT: 17 had subcapsular posterior cataract in both eyes and eight had tear hyposecretion; one had dramatic fungal panuveitis, four had hemorrhagic complications and five optic disk edema. TBI was significantly associated with the development of subcapsular posterior cataract.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8997588     DOI: 10.1177/112067219600600416

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   1.922


  7 in total

1.  Ocular complications in a young pediatric population following bone marrow transplantation.

Authors:  Mary Ellen Hoehn; Julie Calderwood; Edwin Gannon; Brittany Cook; Richard Rochester; Christine Hartford; Brandon Triplett; Anusha Sunkara; Guolian Kang; R Christopher Walton
Journal:  J AAPOS       Date:  2018-01-05       Impact factor: 1.220

2.  Ocular Complications in School-Age Children and Adolescents after Allogeneic Bone Marrow Transplantation.

Authors:  Mary Ellen Hoehn; Robert Vestal; Julie Calderwood; Edwin Gannon; Brittany Cook; Richard Rochester; Christine Hartford; Brandon Triplett; Anusha Sunkara; Guolian Kang; R Christopher Walton
Journal:  Am J Ophthalmol       Date:  2020-03-12       Impact factor: 5.258

3.  Ocular complications in children after hematopoietic stem cell transplantation without total body irradiation.

Authors:  Michael Kinori; Bella Bielorai; Daniel Souroujon; Dafna Hutt; Iris Ben-Bassat Mizrachi; Ruth Huna-Baron
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-02-24       Impact factor: 3.117

4.  The Risk of Cataract among Survivors of Childhood and Adolescent Cancer: A Report from the Childhood Cancer Survivor Study.

Authors:  Gabriel Chodick; Alice J Sigurdson; Ruth A Kleinerman; Charles A Sklar; Wendy Leisenring; Ann C Mertens; Marilyn Stovall; Susan A Smith; Rita E Weathers; Lene H S Veiga; Leslie L Robison; Peter D Inskip
Journal:  Radiat Res       Date:  2016-03-29       Impact factor: 2.841

5.  Visual evoked potentials after hematopoietic allogeneic stem cell transplantation in childhood.

Authors:  Alba Lucia Törnquist; Thomas Andersson; Jacek Winiarski; Marita Andersson Grönlund; Kristina Teär Fahnehjelm
Journal:  Clin Neurophysiol Pract       Date:  2017-03-02

6.  Ocular graft versus host disease in allogenic haematopoetic stem cell transplantation in a tertiary care centre in India.

Authors:  Rehan Khan; Sridevi Nair; Tullika Seth; Pravas Mishra; Manoranjan Mahapatra; Tushar Agarwal; Radhika Tandon; Murugesan Vanathi
Journal:  Indian J Med Res       Date:  2015-11       Impact factor: 2.375

7.  Ocular Findings of Pediatric Dry Eye Related to Graft-Versus-Host Disease

Authors:  Pınar Bingöl Kızıltunç; Tuna Çelik Büyüktepe; Fatime Nilüfer Yalçındağ; Mehmet Ertem; Elif İnce; Talia İleri; Huban Atilla
Journal:  Turk J Ophthalmol       Date:  2021-06-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.